| Peter H. Davies | |
|---|---|
| Photo placeholder | |
| Affiliations | Feinstein Institutes for Medical Research |
| Country | USA |
| H-index | 150 |
| ORCID | 0000-0002-3048-5510 |
| Research Focus | Alzheimer's Disease |
| Mechanisms | Tau Pathology, NFTs, Protein Phosphorylation |
Peter H. Davies is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Peter H. Davies is a distinguished neuroscientist specializing in tau biology and Alzheimer's disease research, affiliated with the Feinstein Institutes for Medical Research in New York. With an h-index of approximately 150, he is a leading authority on the role of tau protein in neurodegenerative diseases. His research has significantly advanced understanding of tau phosphorylation, aggregation, and the formation of neurofibrillary tangles (NFTs) that characterize Alzheimer's disease pathology.
Davies's research program focuses on understanding the molecular mechanisms underlying tau pathology, including how tau becomes hyperphosphorylated, forms toxic aggregates, and spreads through neural circuits[1]. His work has important implications for developing therapeutic strategies targeting tau pathology in Alzheimer's disease and related tauopathies.
Davies has conducted pioneering research on tau phosphorylation, identifying multiple phosphorylation sites that are abnormal in Alzheimer's disease brain[1]. His work established that specific kinases and phosphatases regulate tau phosphorylation state, and that dysregulation of these enzymes contributes to pathological tau accumulation.
His research has elucidated the structural and biochemical properties of neurofibrillary tangles, demonstrating how hyperphosphorylated tau assembles into paired helical filaments (PHFs) and straight filaments (SFs) that characterize Alzheimer's disease pathology.
Davies's research has informed the development of tau-targeted therapeutic strategies, including kinase inhibitors, tau aggregation inhibitors, and immunotherapy approaches aimed at removing toxic tau species from the brain.
At the Feinstein Institutes for Medical Research, Davies leads a research program investigating the basic biology of tau and translating these findings into potential therapeutic interventions for Alzheimer's disease and related disorders.
Dr. Davies has trained numerous researchers in the field of neurodegenerative diseases. His/her laboratory has hosted postdoctoral fellows, graduate students, and visiting scientists from around the world.
Future research directions include:
Dr. Davies maintains collaborations with:
The study of Peter H. Davies has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.